often have a poor prognosis, although little is known about the prognostic factors.
5
In order to elucidate the prognostic factors of HV and HMB, we studied The nomenclature of EBV-associated T/NK LPDs, however, has been controversial. Patients with 22
sHV in the present study may be synonymous with HV-like lymphoma in WHO classification⁹, and 23 be overlapped with chronic active EBV infection (CAEBV) and EBV-associated haemophagocytic 24 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 NK cell-predominant type, and that late onset may be a risk factor 10 . In the present study, we 5 attempted to clarify cellular and molecular markers related to the prognosis of cutaneous 6 EBV-associated T/NK LPDs in a series of patients with HV and HMB, and to verify the validity of 7 diagnostic criteria to distinguish benign from malignant types for the purposes of prognosis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w were selected in the BamHI M region (BMRF1). The upstream and downstream primer sequences 23
were 5'-GTGCCAATCTTGAGGTTTTAC-3' and 5'-CACCCGGGGACTTTTATC-3', respectively. 24 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Immunophenotyping of infiltrating cells 4
Deparafinized biopsy specimens were incubated with monoclonal antibodies to CD3ε, CD4, CD8, 5 CD20, CD30 (DAKO, Tokyo) and CD56 (Novocastra Laboratories, Ltd; Newcastle Upon Tyne), as 6 described previously¹⁴. 7 8
Flow cytometric analysis for lymphocyte subsets 9
Blood samples from the patients were reacted with fluorescence-conjugated antibodies to CD3, 10 CD56, TCRαβ, and TCRγδ (BECKMAN COULTER; California), and analyzed using a FACS 11
Calibur flow cytometer and CellQuest software, version 5.2.1 (Becton Dickinson; New Jersey). 12
13

Statistical analysis 14
Analyses were performed using SPSS for Windows version 20.0 (SPSS 
Results
20
Clinical observations of the patients 21
Fifty patients (26 males and 24 females) were enrolled in the current study. They were classified into 22 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Mucocutaneous symptoms such as conjunctivitis and oral aphthous stomatitis/gingivitis were 6 observed in 6 (26.1%) of 23 cHV patients and 5 (41.7%) of 12 sHV patients, but were not observed 7 in any (0%) of the 9 HMB patients or any (0%) of the 6 HMB+HV. Of 27 patients in the sHV, HMB 8 only, and HMB+HV patients, 22 patients presented with systemic symptoms, including fever (22 9 patients; 81.5%), diarrhea (2 patients; 7.4%), intestinal perforation (1 patient; 3.7%), 10 hepatosplenomegaly (7 patients; 25.9%), myocarditis (2 patients; 7.4%), and hemophagocytic 11 syndrome (2 patients; 7.4%) ( Table 2) . 12
Follow-up study 13
Of 50 patients enrolled in the present study, a follow-up study was possible in a total of 30 patients; 14 time to follow-up ranged from 1 to 26 years (median: 6.5 years). Median follow-up times for the 4 15 groups were: 8 years for cHV, 7 years for sHV, 3 years for HMB only, and 12 years for HMB+HV. 16
All 11 patients with cHV were alive at follow-up, with or without disease, and 9 of the 11 patients 17 had been treated only with sunscreen. One of the 2 remaining patients, a 4-year-old girl with cHV, 18 progressed to sHV in the follow-up period due to an episode of fever associated with rash, and 19 underwent hematopoietic stem cell transplantation (HSCT) 15. The patient had no BZLF1 mRNA 20 expression in the skin lesions, and 83.6% of the γδT cell fraction were positive for EBV infection. 21
Of 19 patients with sHV, HMB, and HMB+HV, 7 (36.8%) died during the follow-up period, 22 including 3 of 8 patients (37.5%) with sHV, 2 of 6 patients (33.3%) with HMB only, and 2 of 5 23 F o r P e e r R e v i e w patients (40%) with HMB+HV. The main cause of death was HSCT-related in at least 2 patients and 1 was multi-organ failure in another 3 patients. 2
Fatalities were observed only in groups with systemic symptoms such as sHV, HMB only and 3 HMB+HV, and not in the cHV group (Fig. 1) . The log-rank test demonstrated a poor prognosis in 4 patients with sHV and HMB only compared to those with cHV (p=0.016 and p=0.015, respectively). 5
Patients with cHV were distinct from the other 3 groups in terms of prognosis (p=0.026), but no 6 significant difference in prognosis was observed between the HV group and HMB group (p=0.286). 7
The number of fatal cases increased gradually over 10 years and did not plateau, except in 8 patients with cHV, who showed no fatalities. The cumulative survival rates reached below 50% in 9 4 years in patients with HMB only, 9 years in sHV, and 14 years in HMB+HV. There was a 10 significant difference in cumulative survival between the groups with HMB only and sHV 11 (p=0.031). 12
Blood test results related to each group 13
Routine laboratory test results upon diagnosis showed no significant differences between the groups 14 in white blood cell count (WBC), hemoglobin (Hb) or aspartate aminotransferase (AST) ( Table 2) . 15
In the HMB only group, however, 3 of 6 patients (50%) had platelet counts below 15×10⁴/ µL and 16 higher serum levels of lactate dehydrogenase (LD) than the cHV or sHV subgroups (p<0.05, 17 respectively). Patients with sHV showed elevated levels of AST, ALT and LD to varying degrees, 18
and hematologic abnormalities such as leukopenia and thrombocytopenia, suggestive of 19 hemophagocytic syndrome. 20
Lymphocyte subsets in PBMCs, taken together with the additional data described in our previous 21 research³, revealed that 10 of 11 patients (90.9%) with HV-like cutaneous lesions, whether in cHV or 22 sHV, showed elevated γδT cell percentages of over 5% (range: 2.18% to 25%), while 12 of 13 23 Antibody titres against EBV-related antigens as determined by immunofluorescence study 3 demonstrated no differences in EBV nuclear antigen (EBNA); however, IgG titres against anti-early 4 antigen (EA) and IgG-class anti-viral capsid antigen (VCA) were slightly higher in the HMB+HV 5 subgroup than those in the cHV and sHV (p<0.05) , and those in the cHV and HMB only groups 6 (p<0.05), respectively 7
The EBV DNA load in PBMCs, as determined by qRT-PCR, was less than 100 copies/µg DNA 8 in healthy individuals, but higher than the reference values in all 26 samples from our patients. The 9 range was from 770 to 720,000 copies /µg DNA, with a mean value of 67,420 ± 140,224 copies /µg 10 DNA. There were no statistically significant differences among the patient's groups (Table2). 11
Histopathologic examinations 12
The percentages of EBER + cells varied even though in the same disease group, ranging from 1% to 13 25% of the infiltrating mononuclear cells in all but 2 of 21 patients. In the 2 exceptional cases, more 14 than 25% EBER + cells were observed in the infiltrates in one sHV and one cHV patients. No 15 difference was observed in the number of EBER + cells among the cHV, sHV, and HMB only groups. 16
The number of samples in the HMB+HV group was insufficient for statistical analysis. 17
In agreement with our previous report³, CD3ε
+ and CD56 -T-cells were predominantly infiltrating 18 in HV lesions, without correlation to the severity of the cutaneous lesions. In HMB lesions, however, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We also evaluated prognostic factors by univariate analysis (Table 3) 
The mortality rate for patients under 9 years was 8.3%, much lower than for those over 9 years, 8 in whom it jumped to 83.3% (p=0.001) (Fig. 2) . Among patients with cHV and sHV, a poor 9 prognosis was observed in those over 9 years of age (p=0.0041). Because a good prognosis is 10 expected with cHV, we recalculated the mortality rates excluding cHV patients. However, the 11 significance of the age-related difference (those under versus over 9 years) remained (p=0.0095). 12
This suggests that an onset age over 9 years is a risk factor. 13
BZLF-1 as a molecular indicator of poor prognosis 14
The expression of EBV-encoded BZLF-1 mRNA, an immediate-early gene product, was detected in 15 the skin lesions of patients in the sHV, HMB only, and HMB+HV groups, while no BZLF1 mRNA 16 expression was observed in any of the 13 cHV patients (Fig. 3) . The positivity rate of BZLF-1 17 mRNA expression was significantly high in the 3 groups with systemic symptoms (33%, p=0.047). 18
No difference was observed in BZLF-1 mRNA expression among the 3 groups. 19
Among EBV-related molecules, the expression of EBV-encoded BZLF-1 in the skin lesions was 20 statistically correlated to a poor prognosis (p=0.003): 4 of 5 (80%) BZLF1 mRNA + patients, and 2 of 21 23 (8.7%) BZLF-1 mRNA -patients died during follow-up, respectively (Fig. 3 ). Among the 25 22 patients who could be followed-up, Kaplan-Meier analysis confirmed that BZLF1 mRNA + patients 23 
Discussion
10
Our research demonstrated that patients with cHV showed a favourable prognosis with 100% 11 survival, and were distinct in this way from the other 3 groups, sHV, HMB only, and HMB+HV, in 12 which approximately one-third of patients had died by end of the follow-up period. Therefore, the 13 cHV criteria used for the present study, i.e., 'typical cutaneous lesions of HV without systemic 14 symptoms or abnormalities in routine laboratory tests results,' are valid criteria for distinguishing 15 benign disease from those with fatal potential. However, it is important to remember that patients 16 with typical HV lesions may progress to systemic forms with fatal outcomes, as previously reported². 17
In terms of disease progression, HMB only may result in fatal outcome within the first 5 years, sHV 18 may progress later, and cases with episodes of both HV and HMB may also require a longer period 19 for progression. 20
Our univariate analysis of patients demonstrated 2 risk factors: 1) onset age of over 9 years, and 21 contrast, no prognostic correlation was observed for EBV-infected lymphocyte subsets, anti-EBV 23 antibody titres, or EBV DNA load, although these parameters would be useful for a diagnostic test or 24 There was a clear difference in mortality rate between age groups: the rate for patients under 9 2 years was 8.3%, while that for patients over 9 years was 83.3% (p<0.001). Because cHV with a 3 favourable prognosis occurred in the first decade, we recalculated the mortality rates excluding cHV 4 patients. The results still showed a significant difference between the under/over 9-years categories 5 (p=0.0041). We, therefore, conclude that onset age may be a risk factor. This supports the findings of 6 a previous report on CAEBV in which onset age over 8 years was one of the prognostic factors 10 . 7
Our analyses indicate that the possibility of disease progression should be considered for patients 8 over 9 years at onset. 9
In addition to late onset, BZLF-1 mRNA expression was closely related to more severe disease 10 conditions and poorer prognosis. BZLF-1 is an immediate early gene product that induces EBV 11 reactivation, with subsequent generation of the lytic cycle infection-associated viral antigens, which 12 evoke CTL responses 16 . Although a previous report has described that BZLF-1 expression was 13 associated with the proliferation of transformed lymphocytes 17 , our observations indicate that fatal 14 outcomes may be related to HPS and multi-organ failure mediated by host immune reactions, but not 15 to the tumour burden evaluated by EBV DNA load or serum LD levels. Therefore, BZLF-1 may be 16 important as both a pathogenic molecule that accounts for systemic symptoms and a prognostic 17 marker. 18 Mayumi Akazawa (Okayama Saiseikai General Hospital), Naoko Kawahara, Katsuhiko Ika, 6
Toshiharu Mitsuhashi, Hiroshi Umemura, Toshihide Tsuda (Okayama University), Yoshinori Ito, 7
Hiroshi Kimura (Nagoya University) and Shinji Murakami (Ehime University). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All patients with cHV survived during the observation period. Patients with cHV showed 3 significantly better prognosis than patients with sHV or HMB only by log-rank test (p=0.016 and 4 p=0.015), and rather good prognosis as compared with the other 3 groups (p=0.026) (a, b). There 5 was no significant difference of the survival time between patients with only HV or HV-like 6 eruptions and patients with HMB (p=0.286) (c). 7
Fig. 2. Onset age and mortality rates. 8
There was a clear difference in mortality rates: patients under 9 years had mortality of 8.3%, while 9 those over 9 years had a mortality of 83.3% (p<0.001) (a). In the group of patients with cHV or sHV, 10 patients over 9 years also showed a poor prognosis (p=0.0041) (b). Even when cHV patients with 11 favorable outcome were excluded, the significant difference in mortality rates between patients 12 under and over 9 years remained (p=0.0095) (c). 13 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 There was a clear difference in mortality rates: patients under 9 years had mortality of 8.3%, while those over 9 years had a mortality of 83.3% (p<0.001) (a). In the group of patients with cHV or sHV, patients over 9 years also showed a poor prognosis (p=0.0041) (b). Even when cHV patients with favorable outcome were excluded, the significant difference in mortality rates between patients under and over 9 years remained (p=0.0095) (c). 30x17mm (300 x 300 DPI) No BZLF-1 mRNA expression was observed in the skin lesions of the 13 patients with cHV, while BZLF-1 mRNA was detected in 5 of the 15 (33.3%) of patients with sHV, HMB only, and HMB+HV (p=0.047) (a). The log rank test demonstrated that BZLF-1 mRNA+ cases showed significantly worse prognosis than BZLF-1 mRNA-cases (p=0.012). Among the 25 patients who could be followed-up, the 10-year survival rate was significantly worse in the BZLF-1 mRNA+ cases by log-rank test (26.7% vs 95%, p=0.003) (b). 30x22mm (300 x 300 DPI)
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HPS ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Univariate analysis of factors related to the mortality of cHV, sHV, HMB only and HMB+HV Abbreviations: VCA, viral capsid antigen; EA, early antigen; EBNA, Epstein-Barr nuclear antigen; HSCT, hematopoietic stem cell transplantation; *P value were obtained by use of either Fisher exact test or Mann-Whitney U test. Laboratory data were determined at the time of diagnosis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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